BridgeBio Pharma (BBIO) Competitors $22.90 -0.14 (-0.61%) (As of 10:25 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends BBIO vs. BHVN, TPTX, PRGO, FOLD, BPMC, VTRS, MRNA, GMAB, SMMT, and RDYShould you be buying BridgeBio Pharma stock or one of its competitors? The main competitors of BridgeBio Pharma include Biohaven (BHVN), Turning Point Therapeutics (TPTX), Perrigo (PRGO), Amicus Therapeutics (FOLD), Blueprint Medicines (BPMC), Viatris (VTRS), Moderna (MRNA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "medical" sector. BridgeBio Pharma vs. Biohaven Turning Point Therapeutics Perrigo Amicus Therapeutics Blueprint Medicines Viatris Moderna Genmab A/S Summit Therapeutics Dr. Reddy's Laboratories Biohaven (NYSE:BHVN) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, community ranking, profitability, earnings, analyst recommendations, valuation and risk. Does the MarketBeat Community favor BHVN or BBIO? Biohaven received 233 more outperform votes than BridgeBio Pharma when rated by MarketBeat users. However, 70.56% of users gave BridgeBio Pharma an outperform vote while only 66.89% of users gave Biohaven an outperform vote. CompanyUnderperformOutperformBiohavenOutperform Votes39666.89% Underperform Votes19633.11% BridgeBio PharmaOutperform Votes16370.56% Underperform Votes6829.44% Do insiders and institutionals have more ownership in BHVN or BBIO? 88.8% of Biohaven shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 16.0% of Biohaven shares are held by company insiders. Comparatively, 24.7% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts rate BHVN or BBIO? Biohaven presently has a consensus target price of $63.42, indicating a potential upside of 35.48%. BridgeBio Pharma has a consensus target price of $47.57, indicating a potential upside of 106.47%. Given BridgeBio Pharma's higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than Biohaven.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biohaven 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 3.07BridgeBio Pharma 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.87 Which has higher earnings and valuation, BHVN or BBIO? Biohaven has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiohaven$462.51M10.23-$408.17M-$9.35-5.01BridgeBio Pharma$9.30M468.21-$643.20M-$2.41-9.56 Is BHVN or BBIO more profitable? Biohaven has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -201.53%. BridgeBio Pharma's return on equity of 0.00% beat Biohaven's return on equity.Company Net Margins Return on Equity Return on Assets BiohavenN/A -225.12% -158.89% BridgeBio Pharma -201.53%N/A -74.34% Which has more risk & volatility, BHVN or BBIO? Biohaven has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Does the media refer more to BHVN or BBIO? In the previous week, BridgeBio Pharma had 21 more articles in the media than Biohaven. MarketBeat recorded 32 mentions for BridgeBio Pharma and 11 mentions for Biohaven. Biohaven's average media sentiment score of 0.34 beat BridgeBio Pharma's score of 0.17 indicating that Biohaven is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 8 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryBiohaven and BridgeBio Pharma tied by winning 9 of the 18 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BBIO vs. The Competition Export to ExcelMetricBridgeBio PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.35B$6.45B$5.06B$8.82BDividend YieldN/A8.11%5.18%4.07%P/E Ratio-9.5610.78126.3117.81Price / Sales468.21243.711,178.7474.57Price / CashN/A22.1633.8632.53Price / Book-2.985.474.684.68Net Income-$643.20M$153.61M$119.54M$226.08M7 Day Performance-4.44%-2.00%-1.83%-1.04%1 Month Performance-8.43%-7.46%-3.60%1.04%1 Year Performance-18.62%31.82%31.91%26.28% BridgeBio Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BBIOBridgeBio Pharma4.5795 of 5 stars$22.90-0.6%$47.57+107.7%-21.2%$4.33B$9.30M-9.50400Insider TradeAnalyst RevisionBHVNBiohaven3.9207 of 5 stars$45.56-2.7%$63.42+39.2%+53.0%$4.61B$462.51M0.00239TPTXTurning Point TherapeuticsN/A$76.01flatN/A+0.0%$3.81B$30.83M-11.02250PRGOPerrigo4.9834 of 5 stars$26.92-0.8%$37.00+37.4%-10.8%$3.67B$4.66B-23.209,140News CoveragePositive NewsFOLDAmicus Therapeutics4.6221 of 5 stars$9.45-1.5%$17.63+86.5%-13.1%$2.82B$399.36M-28.09480BPMCBlueprint Medicines2.713 of 5 stars$94.03-0.8%$122.11+29.9%+43.9%$5.97B$249.38M0.00640Analyst ForecastAnalyst RevisionVTRSViatris1.3514 of 5 stars$13.16+0.2%$13.33+1.3%+38.6%$15.71B$15.43B0.0038,000MRNAModerna4.6292 of 5 stars$36.66-0.8%$84.00+129.1%-53.2%$14.11B$6.85B-6.355,600Analyst UpgradeAnalyst RevisionGMABGenmab A/S4.3164 of 5 stars$20.50+0.2%$45.20+120.5%-37.0%$13.57B$2.39B19.852,204SMMTSummit Therapeutics1.8779 of 5 stars$18.25-2.0%$34.75+90.4%+835.7%$13.46B$700,000.00-67.00105Analyst ForecastRDYDr. Reddy's Laboratories1.3294 of 5 stars$14.07-1.6%$17.00+20.8%+5.9%$11.74B$3.35B22.8427,048 Related Companies and Tools Related Companies Biohaven Alternatives Turning Point Therapeutics Alternatives Perrigo Alternatives Amicus Therapeutics Alternatives Blueprint Medicines Alternatives Viatris Alternatives Moderna Alternatives Genmab A/S Alternatives Summit Therapeutics Alternatives Dr. Reddy's Laboratories Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BBIO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BBIO Stock Alerts